对已知基因突变（纤溶酶原和 XII 因子）患者的临床评估，重点是预防性治疗

IF 2.9 4区医学 Q2 DERMATOLOGY

Journal of Dermatological Treatment Pub Date : 2023-12-12 DOI:10.1080/09546634.2023.2290362

Robin Lochbaum, Susanne Trainotti, Thomas K. Hoffmann, Jens Greve, Janina Hahn

引用次数: 0

摘要

具有正常c1抑制剂(HAE-nC1-INH)的遗传性血管性水肿是一种罕见的遗传病。其症状可能类似于其他形式的遗传性血管性水肿(HAE)，但具体的实验室值是…

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

A clinical evaluation of patients with known mutations (plasminogen and factor XII) with a focus on prophylactic treatment

Hereditary angioedema with normal C1-inhibitor (HAE-nC1-INH) is a rare genetic disease. The symptoms can resemble other forms of hereditary angioedema (HAE), but the specific laboratory values are ...

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Dermatological Treatment 医学-皮肤病学

CiteScore

6.50

自引率

0.00%

发文量

145

审稿时长

6-12 weeks

期刊介绍： The Journal of Dermatological Treatment covers all aspects of the treatment of skin disease, including the use of topical and systematically administered drugs and other forms of therapy. The Journal of Dermatological Treatment is positioned to give dermatologists cutting edge information on new treatments in all areas of dermatology. It also publishes valuable clinical reviews and theoretical papers on dermatological treatments.